<DOC>
	<DOCNO>NCT00578591</DOCNO>
	<brief_summary>This prospective , open-label pilot study 4 dos Rituximab administer patient develop SR-aGVHD follow allogeneic hematopoietic transplant ( AHT ) . The study design determine overall survival 180 day treatment rituximab , evaluate safety clinical response rituximab study population . Study entry : Patients must enter study day +100 posttransplant .</brief_summary>
	<brief_title>Rituximab GVHD</brief_title>
	<detailed_description>Acute graft-versus-host disease ( aGVHD ) , one important complication allogeneic hematopoietic stem cell transplantation ( HSCT ) associate significant morbidity mortality . Grades II IV aGVHD occur 30 % 50 % match related donor recipient 50 % 70 % unrelated donor recipient . Standard first-line treatment consist methylprednisolone dose 2 mg/kg/d equivalent produce response rate 63 % 95 % grade II , 17 % 39 % grade III , 0 % 6 % grade IV aGVHD . In aggregate , approximately 40 % 50 % patient acute GVHD experience complete partial response primary therapy , whereas 20 % 60 % require salvage treatment . The 1994 consensus conference acute GVHD grading report 100-day survival rate 78 % 90 % grade I , 66 % 92 % grade II , 29 % 62 % grade III , 23 % 25 % grade IV . The high mortality rate directly attributable acute GVHD subsequent immunosuppression high-dose corticosteroid medication require treatment GVHD . Despite several study seek improve first-line therapy acute GVHD , standard care remain moderate-dose corticosteroid . Higher initial dos corticosteroid , prolong steroid tapering course , addition murine equine anti-T-cell antibody standard GVHD therapy fail improve response rate . Acute GVHD therefore remain unfavorable complication transplantation difficult manage . Various immunosuppressant include , Anti-thimocyte globulin ( ATG ) , Denileukin Diftitox , Mycophenolate mofetil , Pentostatin , Infliximab , Rapamycin , Inolimomab Daclizumab try variable success ( table-1 full protocol ) ; remain consensus second-line treatment aGVHD . Acute graft-versus-host-disease ( aGVHD ) mediate donor T-cells . The preventative therapeutic strategy describe therefore focused quantitative reduction T cell reduction function immune-modulation . The role B-lymphocytes pathogenesis GHVD unclear . Recent report successful use rituximab cGVHD support hypothesis coordinate B T cell response instrumental cGVHD . The significance B-cells pathogenesis aGVHD unknown . Steroid Refractory Acute Graft-Versus-Host-Disease ( SR-aGVHD ) Initial treatment aGVHD routinely consist intensify dose corticosteroid . This condition call steroid-resistant ( SR ) aGVHD require secondary intervention . Rituximab human/murine chimeric monoclonal anti CD-20 antibody extensively use patient B-cell non-Hodgkin 's lymphoma , autoimmune disease . The incidental observation improvement aGVHD follow rituximab infusion transplant-associated thrombotic thrombocytopenic purpura ( TA-TTP ) subsequent complete resolution multi-agent refractory aGVHD two patient forms basis propose pilot study . Table-2 ( full protocol ) describe patient response rituximab institution .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Diagnosis acute graftversushost disease ( aGVHD ) 2 . Steroidrefractory aGVHD follow : ) No change stage skin aGVHD 1 week 2 mg/kg per day methylprednisolone . b ) Progression acute GVHD ( ie , increase disease stage least 1 ) skin GVHD lack response visceral ( liver , GI ) aGVHD despite treatment 2 mg/kg per day methylprednisolone least 72 hour . c ) Progression visceral aGVHD despite treatment 2 mg/kg per day methylprednisolone least 48 hour ) Visceral aGVHD progress stage 4 24 hour 2 mg/kg per day methylprednisolone . 3 . Grade IIIV aGVHD require systemic therapy within 2448 hour diagnosis . Biopsy confirmation aGVHD strongly recommend require ; enrollment delay await biopsy pathology result . 4 . Patients must receive corticosteroid great equal 2 mg/kg/day minimum 72 hour prior study entry ( firstline aGVHD treatment ) . 5 . ANC great 500/uL x 3 day ( must evidence engraftment ) . 6 . Patient &lt; 100 day posttransplant 7 . Any age , sex , ethnicity . 8 . Karnofsky score/Lansky score great 20 9 . Men woman childbearing potential must use adequate birth control measure ( e.g. , abstinence , oral contraceptive , intrauterine device , barrier method spermicide , surgical sterilization ) duration study continue precaution 6 month receive study drug infusion . 10 . Parent ( ) /legal guardian must give informed consent . 1 . Chronic GVHD ( define GVHD occur beyond 100 day hematopoietic transplant ) . 2 . Isolated upper gastrointestinal GVHD sole manifestation acute GVHD . 3 . Isolated grade I II skin GVHD sole manifestation aGVHD . 4 . GVHD follow donor lymphocyte infusion ( DLI ) . 5 . Other investigational agent treatment prophylaxis GVHD within past 2 week . An investigational drug define one give study , require inform consent . 6 . Use rituximab condition regimen hematopoietic transplant . 7 . Prophylactic immunosuppression taper stop treatment leukemia relapse minimal residual disease . 8 . Patients uncontrolled infection ( ) i.e . document bacterial , viral fungal infection within 72 hour prior study entry . Neither continuation antibiotic control infection prophylactic/empiric antibiotic warrant exclusion . Patients C. difficile infection exclude . 9 . Patients one follow opportunistic infection document within 8 week prior study entry exclude : pneumocystis carinii , aspergillosis , histoplasmosis , atypical mycobacterium infection pathogenic molds/fungi . 10 . Patients hypotension believe secondary sepsis syndrome heart failure require &gt; 1 inotropic agent , dopamine &gt; 5mcg/kg/minute blood pressure support . 11 . Mechanical ventilatory support . 12 . Relapsed , refractory , second malignancy time study entry . 13 . Previous grade IV severe adverse reaction rituximab . 14 . Any allergy murine product . 15 . Documented HIV HBV infection . 16 . Patients grade IV renal , hepatic , pulmonary , neurologic toxicity National Cancer Institute ( NCI ) Common Toxicity Criteria ( CTC ) . 17 . Patients history congestive heart failure , define cardiac dysfunction require inotropic support dopamine &lt; = 5mcg/kg/minute . 18 . Autologous syngeneic transplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Graft Versus Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>allogeneic hematopoietic transplant</keyword>
	<keyword>AHT</keyword>
	<keyword>posttransplant</keyword>
	<keyword>Rituximab</keyword>
</DOC>